Jiangxi Fushine Pharmaceutical Co., Ltd. (300497.SZ)
CNY 8.16
(0.0%)
CNY 8.16
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.34 Billion CNY | -0.92% |
| 2022 | 2.37 Billion CNY | 34.12% |
| 2021 | 1.76 Billion CNY | 77.09% |
| 2020 | 997.92 Million CNY | -6.59% |
| 2019 | 1.06 Billion CNY | 1.76% |
| 2018 | 1.04 Billion CNY | 27.6% |
| 2017 | 822.7 Million CNY | 33.95% |
| 2016 | 614.19 Million CNY | 48.56% |
| 2015 | 413.44 Million CNY | 18.44% |
| 2014 | 349.08 Million CNY | 12.05% |
| 2013 | 311.54 Million CNY | 6.8% |
| 2012 | 291.7 Million CNY | 25.71% |
| 2011 | 232.04 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 2.26 Billion CNY | 1.32% |
| 2024 Q1 | 2.23 Billion CNY | -4.66% |
| 2024 Q2 | 2.23 Billion CNY | -0.28% |
| 2023 Q3 | 2.33 Billion CNY | 0.48% |
| 2023 Q4 | 2.34 Billion CNY | 0.53% |
| 2023 Q1 | 2.2 Billion CNY | -6.85% |
| 2023 FY | 2.34 Billion CNY | -0.92% |
| 2023 Q2 | 2.32 Billion CNY | 5.29% |
| 2022 Q4 | 2.37 Billion CNY | 6.82% |
| 2022 Q3 | 2.21 Billion CNY | 3.14% |
| 2022 Q2 | 2.15 Billion CNY | 3.14% |
| 2022 FY | 2.37 Billion CNY | 34.12% |
| 2022 Q1 | 2.08 Billion CNY | 18.03% |
| 2021 Q1 | 1.11 Billion CNY | 11.97% |
| 2021 Q3 | 1.37 Billion CNY | 8.96% |
| 2021 Q4 | 1.76 Billion CNY | 28.76% |
| 2021 FY | 1.76 Billion CNY | 77.09% |
| 2021 Q2 | 1.25 Billion CNY | 12.72% |
| 2020 Q1 | 1.06 Billion CNY | 0.07% |
| 2020 FY | 997.92 Million CNY | -6.59% |
| 2020 Q4 | 997.92 Million CNY | 8.81% |
| 2020 Q3 | 917.11 Million CNY | -5.45% |
| 2020 Q2 | 969.99 Million CNY | -9.27% |
| 2019 Q2 | 1.28 Billion CNY | 0.9% |
| 2019 Q1 | 1.27 Billion CNY | 21.35% |
| 2019 FY | 1.06 Billion CNY | 1.76% |
| 2019 Q4 | 1.06 Billion CNY | -11.39% |
| 2019 Q3 | 1.2 Billion CNY | -6.21% |
| 2018 Q3 | 924.98 Million CNY | -7.88% |
| 2018 Q2 | 1 Billion CNY | 17.92% |
| 2018 Q1 | 851.54 Million CNY | 3.51% |
| 2018 FY | 1.04 Billion CNY | 27.6% |
| 2018 Q4 | 1.04 Billion CNY | 13.49% |
| 2017 Q3 | 796.17 Million CNY | 5.54% |
| 2017 Q4 | 822.7 Million CNY | 3.33% |
| 2017 Q2 | 754.36 Million CNY | 14.54% |
| 2017 Q1 | 658.59 Million CNY | 7.23% |
| 2017 FY | 822.7 Million CNY | 33.95% |
| 2016 Q2 | 490.28 Million CNY | 30.78% |
| 2016 Q4 | 614.19 Million CNY | 54.13% |
| 2016 Q3 | 398.5 Million CNY | -18.72% |
| 2016 Q1 | 374.88 Million CNY | -9.33% |
| 2016 FY | 614.19 Million CNY | 48.56% |
| 2015 Q3 | 391.42 Million CNY | 3.61% |
| 2015 FY | 413.44 Million CNY | 18.44% |
| 2015 Q4 | 413.44 Million CNY | 5.63% |
| 2015 Q1 | 355.45 Million CNY | 1.83% |
| 2015 Q2 | 377.78 Million CNY | 6.28% |
| 2014 Q4 | 349.08 Million CNY | 0.0% |
| 2014 Q1 | - CNY | 0.0% |
| 2014 FY | 349.08 Million CNY | 12.05% |
| 2013 FY | 311.54 Million CNY | 6.8% |
| 2012 FY | 291.7 Million CNY | 25.71% |
| 2011 FY | 232.04 Million CNY | 0.0% |